(Q35850708)

10 August 2017

0 references

Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS (English)

1 reference

10 August 2017

0 references

Philipp von Rosenstiel

14

Philipp von Rosenstiel

1 reference

10 August 2017

Till Sprenger

11

0 references

Helmut Butzkueven

Helmut Butzkueven

5

0 references

Heinz Wiendl

Heinz Wiendl

6

0 references

Hans-Peter Hartung

8

Hans-Peter Hartung

1 reference

10 August 2017

1

Ludwig Kappos

1 reference

10 August 2017

3

Giancarlo Comi

1 reference

10 August 2017

7

Gavin Giovannoni

1 reference

10 August 2017

2

Ernst-Wilhelm Radue

1 reference

10 August 2017

4

Xavier Montalban

1 reference

10 August 2017

15

Rebecca Gottschalk

1 reference

10 August 2017

17

Frank Dahlke

1 reference

10 August 2017

18

Davorka Tomic

1 reference

10 August 2017

12

Nicole Mueller-Lenke

1 reference

10 August 2017

10

Yvonne Naegelin

1 reference

10 August 2017

9

Tobias Derfuss

1 reference

10 August 2017

Sarah Griffiths

13

1 reference

10 August 2017

Ying Zhang

16

1 reference

10 August 2017

TOFINGO study group

19

1 reference

10 August 2017

language of work or name

English

0 references

publication date

29 May 2015

1 reference

10 August 2017

1 reference

10 August 2017

85

1 reference

10 August 2017

1

1 reference

10 August 2017

29-39

1 reference

Fingolimod in relapsing multiple sclerosis: An integrated analysis of safety findings

10 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4501941

Compositional changes of B and T cell subtypes during fingolimod treatment in multiple sclerosis patients: a 12-month follow-up study

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4501941

Relapses in patients treated with fingolimod after previous exposure to natalizumab

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4501941

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4501941

MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4501941

Fingolimod after natalizumab and the risk of short-term relapse

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4501941

Risk of natalizumab-associated progressive multifocal leukoencephalopathy

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4501941

Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4501941

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4501941

Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4501941

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4501941

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4501941

Abnormal inflammatory activity returns after natalizumab cessation in multiple sclerosis

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4501941

Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4501941

Reduction of the washout time between natalizumab and fingolimod.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4501941

Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4501941

Declaration of Helsinki. Ethical principles for medical research involving human subjects.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4501941

FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4501941

Immune surveillance in multiple sclerosis patients treated with natalizumab.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4501941

ICH harmonized tripartite guideline: Guideline for Good Clinical Practice.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4501941

Recurrent disease-activity rebound in a patient with multiple sclerosis after natalizumab discontinuations for pregnancy planning

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4501941

Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis

14 November 2018

1 reference

12 December 2020

Severe relapses under fingolimod treatment prescribed after natalizumab

1 reference

12 December 2020

Switching from natalizumab to fingolimod: an observational study

1 reference

12 December 2020

World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects

1 reference

12 December 2020

10.1212/WNL.0000000000001706

Identifiers

DOI

1 reference

10 August 2017

1 reference

10 August 2017

PubMed publication ID

26024899

1 reference